Ultragenyx Pharmaceutical | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
Acadia Pharmaceuticals USD 223.92M 13.87M 2025-03
Agios Pharmaceuticals USD 7.64M 1.83M 2025-03
Alnylam Pharmaceuticals USD 523.15M 32.8M 2025-03
BioMarin Pharmaceutical USD 593.59M 17.59M 2025-03
Insmed USD 71.54M 6.75M 2025-03
Ionis Pharmaceuticals USD 130.15M 92.6M 2025-03
Kyowa Hakko Kirin JPY 80.14B 15.15B 2025-03
MacroGenics USD 13.86M 94.98M 2024-12
Moderna USD 17M 403M 2025-03
Neurocrine Biosciences USD 618.4M 4.3M 2024-12
PTC Therapeutics USD 196.89M 10.95M 2024-12
Regeneron Pharmaceuticals USD 2.56B 659.4M 2025-03
Sarepta Therapeutics USD 607.29M 81.18M 2025-03
Ultragenyx Pharmaceutical USD 110.63M 37.35M 2025-03
Vertex Pharmaceuticals USD 2.49B 109.3M 2024-12



Ultragenyx Pharmaceutical Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - May 2025.